A double - blind , randomized , controlled , multicenter safety and immunogenicity study of a refrigerator - stable formulation of Zostavax . 
<br>
<br> The vaccine Zostavax has been shown to prevent herpes zoster ( HZ ) and postherpetic neuralgia and is recommended for individuals > or = 60 years of age . This study compared the <font color="blue">safety_1</font> and the immunogenicity of a refrigerator - stable formulation ( Zostavax refrigerated ) with those of the current formulation ( Zostavax frozen ) in subjects > or = 50 years of age . Subjects with a negative history for HZ were randomized 1:1 to receive one dose of either formulation . Enrollment was stratified 1:2 by age ( 50 to 59 years and > or = 60 years ) . <font color="blue">Safety_1</font> was evaluated for 28 days postvaccination . <font color="blue">Varicella_2</font> <font color="blue">-_2</font> <font color="blue">zoster_2</font> <font color="blue">virus_2</font> <font color="blue">(_2</font> <font color="blue">VZV_2</font> <font color="blue">)_2</font> <font color="blue">antibody_2</font> <font color="blue">responses_2</font> were measured by a glycoprotein enzyme - linked immunosorbent assay ( gpELISA ) . The primary endpoints were the <font color="blue">VZV_4</font> <font color="blue">antibody_4</font> <font color="blue">geometric_4</font> <font color="blue">mean_4</font> <font color="blue">titer_4</font> ( <font color="blue">GMT_1</font> <font color="blue">;_1</font> <font color="blue">day_1</font> <font color="blue">28_1</font> <font color="blue">)_1</font> , the <font color="blue">VZV_4</font> <font color="blue">antibody_4</font> <font color="blue">geometric_4</font> <font color="blue">mean_4</font> <font color="blue">rise_4</font> ( <font color="blue">GMR_1</font> <font color="blue">;_1</font> <font color="blue">days_1</font> <font color="blue">1_1</font> <font color="blue">to_1</font> <font color="blue">28_1</font> <font color="blue">)_1</font> , and the <font color="blue">incidence_3</font> <font color="blue">of_3</font> <font color="blue">vaccine_3</font> <font color="blue">-_3</font> <font color="blue">related_3</font> <font color="blue">serious_3</font> <font color="blue">adverse_3</font> <font color="blue">experiences_3</font> <font color="blue">(_2</font> <font color="blue">AEs_2</font> <font color="blue">)_2</font> over 28 days . The refrigerated ( n = 182 ) and frozen ( n = 185 ) formulations induced <font color="blue">similar_1</font> <font color="blue">GMTs_2</font> ( 727.4 and 834.4 gpELISA units / ml , respectively ) ; the <font color="blue">estimated_1</font> <font color="blue">GMT_4</font> <font color="blue">ratio_3</font> <font color="blue">(_3</font> <font color="blue">refrigerated_3</font> <font color="blue">formulation_3</font> <font color="blue">/_3</font> <font color="blue">frozen_3</font> <font color="blue">formulation_3</font> <font color="blue">)_3</font> was 0.87 ( 95% confidence interval , 0.71 to 1.07 ) . The <font color="blue">GMRs_2</font> were 2.6- and 2.9-fold , respectively . <font color="blue">No_1</font> <font color="blue">vaccine_4</font> <font color="blue">-_4</font> <font color="blue">related_4</font> <font color="blue">serious_4</font> <font color="blue">AEs_4</font> <font color="blue">were_1</font> <font color="blue">reported_1</font> in either group , and the <font color="blue">safety_1</font> <font color="blue">profiles_1</font> of the formulations were generally similar . The <font color="blue">frequencies_3</font> <font color="blue">of_3</font> <font color="blue">injection_3</font> <font color="blue">-_3</font> <font color="blue">site_3</font> <font color="blue">AEs_4</font> during follow - up were 35.6% and 46.4% in the refrigerated and the frozen formulation groups , respectively , and were <font color="blue">generally_1</font> <font color="blue">mild_1</font> <font color="blue">._1</font> The <font color="blue">frequencies_3</font> <font color="blue">of_3</font> <font color="blue">systemic_4</font> <font color="blue">AEs_4</font> were <font color="blue">similar_1</font> in the two groups , and those of <font color="blue">vaccine_1</font> <font color="blue">-_1</font> <font color="blue">related_1</font> <font color="blue">AEs_1</font> were approximately 6% in both groups . The refrigerator - stable formulation of Zostavax has an acceptable safety profile and is as immunogenic as the frozen formulation ; thus , the vaccine may be used in clinical settings where freezer availability is limited .